BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17373880)

  • 1. FOXA1 as a therapeutic target for breast cancer.
    Nakshatri H; Badve S
    Expert Opin Ther Targets; 2007 Apr; 11(4):507-14. PubMed ID: 17373880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.
    Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S
    Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 represses the molecular phenotype of basal breast cancer cells.
    Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
    Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
    Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
    Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
    Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
    Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
    Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERĪ± function.
    Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
    Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
    Jing X; Liang H; Hao C; Hongxia L; Cui X
    Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
    Schrijver W; Schuurman K; van Rossum A; Droog M; Jeronimo C; Salta S; Henrique R; Wesseling J; Moelans C; Linn SC; van den Heuvel M; van Diest P; Zwart W
    Mol Oncol; 2018 Nov; 12(11):1884-1894. PubMed ID: 29972720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
    Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
    Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells.
    Niang B; Jin L; Chen X; Guo X; Zhang H; Wu Q; Padhiar AA; Xiao M; Fang D; Zhang J
    Mol Cell Biochem; 2016 Jan; 411(1-2):393-402. PubMed ID: 26541755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.
    Bernardo GM; Lozada KL; Miedler JD; Harburg G; Hewitt SC; Mosley JD; Godwin AK; Korach KS; Visvader JE; Kaestner KH; Abdul-Karim FW; Montano MM; Keri RA
    Development; 2010 Jun; 137(12):2045-54. PubMed ID: 20501593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
    Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
    Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxA1 as a lineage-specific oncogene in luminal type breast cancer.
    Yamaguchi N; Ito E; Azuma S; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Tatsuta K; Inoue J; Semba K; Watanabe S
    Biochem Biophys Res Commun; 2008 Jan; 365(4):711-7. PubMed ID: 18039470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
    Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas].
    Liu N; Niu Y; Wang SL; Yu Q; Zhang RJ; Liu TJ
    Zhonghua Yi Xue Za Zhi; 2010 May; 90(20):1403-7. PubMed ID: 20646630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP1 and estrogen signaling in breast cancer.
    Ijichi N; Ikeda K; Horie-Inoue K; Inoue S
    Vitam Horm; 2013; 93():203-12. PubMed ID: 23810008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXA1 in breast cancer.
    Nakshatri H; Badve S
    Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
    Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
    Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.